A Regulatory Requirement Non Interventional Study to Monitor the Safety and Effectiveness of JARDIANCE® (Empagliflozin, 10mg, 25mg, q.d.) in Korean Patients With Type 2 Diabetes Mellitus
Phase of Trial: Phase IV
Latest Information Update: 04 May 2017
At a glance
- Drugs Empagliflozin (Primary)
- Indications Diabetes mellitus
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 17 Aug 2016 Status changed from not yet recruiting to recruiting.
- 09 Aug 2016 Planned initiation date changed from 1 Jul 2016 to 1 Aug 2016.
- 01 Aug 2016 New trial record